Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Melanoma × trametinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Glioma 2 Thyroid Carcinoma, Anaplastic 1 Oligodendroglioma 1 Nonseminomatous germ cell tumor 1 Neurocytoma 1 Multiple Myeloma 1 Melanoma 1 Leukemia, Hairy Cell 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Ganglioneuroma 1 Ganglioglioma 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Astrocytoma 1

Interventions

pembrolizumab 4 Nivolumab 3 Vemurafenib 2 Ipilimumab 2 trametinib 1 relatlimab 1 lifileucel 1 larotrectinib 1 entrectinib 1 encorafenib 1 dabrafenib 1 cobimetinib 1 binimetinib 1 atezolizumab 1 Dacarbazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01682083 2023-08-30

COMBI-AD

Novartis

Phase 3 Completed

870 enrolled 13 charts 1 FDA

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡